on HBM Healthcare Investments AG (ETR:CH001262)
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for USD 820 Million
HBM Healthcare Investments has announced that its portfolio company, Bluejay Therapeutics, will be acquired by Mirum Pharmaceuticals. The transaction, valued at up to USD 820 million, includes USD 250 million in cash and USD 370 million in Mirum stock. Additionally, there are potential tiered milestone payments of up to USD 200 million. This deal follows HBM’s USD 7 million investment in Bluejay's Series C round in May 2024.
Upon closing, HBM Healthcare is set to receive approximately USD 6 million in cash, along with Mirum shares valued at USD 7 million. Further potential earnings include up to USD 3.7 million upon reaching specific sales milestones. Bluejay focuses on therapies for viral and liver diseases and is developing brelovitug, an antibody targeting chronic hepatitis D and B.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HBM Healthcare Investments AG news